Lilly says it will raise drug prices in Europe, responding to Trump threats

As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” prices to “align” costs across different countries.

By Jonathan Gardner • Aug. 14, 2025

Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

DTC isn’t converting to Rxs at the pharmacy. Learn how access may be key to your brand’s success.

Aug. 11, 2025

Explore the Trendline➔

Drug pricing

President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.

By BioPharma Dive staff

Drugmakers score policy win in fight against 340B

A new pilot program from HHS will test alterations to the contentious 340B pricing program by swapping traditional upfront drug discounts for rebates.

By Amy Baxter • Aug. 4, 2025

Trump administration to pilot 340B rebate model next year

The pilot departs from the current model, which gives hospitals upfront discounts for some drugs. Hospitals say 340B is a lifeline, while drugmakers claim hospitals have abused the program.

By Susanna Vogel • Aug. 1, 2025

Trump redoubles threats in attempt to strongarm drugmakers on prices

The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for newly launched drugs.

By Jonathan Gardner • July 31, 2025

Apples to apples: Stelara biosimilars and the fight for market share

How will payers determine which Stelara biosimilar to add to their formularies?

By Samantha Ngan, Associate Manager, Market Research, MMIT and Andrew Rouff, Senior Consultant, Advisory Services, MMIT • July 21, 2025

Novartis CEO says resolution on Trump plan to cut US drug prices will take time

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said Thursday. But the details, and their potential consequences, are still not clear.

By Ned Pagliarulo • Updated July 17, 2025

Congress should reconsider breaking up PBMs, experts say

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go after the oligopoly enjoyed by the “Big Three” companies.

By Rebecca Pifer • June 27, 2025

Oz hints at impending CMS rule to force drug price transparency

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug cost information, Oz said.

By Rebecca Pifer • June 24, 2025

GLP-1 prescriptions for weight loss soar, despite obstacles

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, according to a new report.

By Rebecca Pifer • May 28, 2025

House passes reconciliation bill with massive Medicaid cuts

Speaker Mike Johnson negotiated a number of last minute changes to the megabill to get it across the finish line, including moving up the start date for Medicaid work requirements. 

By Rebecca Pifer • May 22, 2025

Bridging the data gaps that impact retail and specialty-lite success

Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.

May 19, 2025

Stopping a ‘moral obscenity’: Senate Judiciary Committee expresses support for PBM reform

Sen. Chuck Grassley, R-Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass President Donald Trump’s conservative megabill this summer.

By Rebecca Pifer • May 15, 2025

5 questions on Trump’s plan to lower US drug prices

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the details on how that will happen are unclear. 

By Jonathan Gardner • May 13, 2025

Trump revives ‘most favored nation’ plan in effort to cut US drug prices

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of discussions with substantial ramifications for drugmakers. It’s likely to be challenged in court, however.

By Jonathan Gardner , Ned Pagliarulo • Updated May 12, 2025

Trump signals plan to address ‘pill penalty’ of drug pricing law

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the industry.

By Kristin Jensen • April 16, 2025

Drug compounders sue FDA over declaration ending Wegovy shortage

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” but in earnings Monday still forecast higher revenue and profits in 2025.

By Jonathan Gardner • Feb. 25, 2025

Trump administration affirms drug price talks, but will seek input to ‘improve’ program

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short CMS statement didn’t clear things up.

By Jonathan Gardner • Updated Jan. 30, 2025

Judge halts Trump freeze on grants as states report healthcare payment portals back online

States and providers regained access to a key healthcare payments portal late Tuesday amid pushback over the Trump administration’s decision to halt federal assistance.

By Rebecca Pifer • Jan. 29, 2025

J&J joins Pfizer in detailing impact of Part D redesign

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.

By Ned Pagliarulo • Jan. 22, 2025

Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

By Jonathan Gardner • Jan. 17, 2025

Ozempic, Ibrance among next drugs picked by Medicare for price talks

Announcement of the 15 medicines chosen for the second round of negotiations was one of the Biden administration’s final health policy acts.

By Ned Pagliarulo • Updated Jan. 17, 2025

FTC again goes after PBMs’ business practices in new report

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.

By Rebecca Pifer • Updated Jan. 14, 2025

As election day nears, Trump and Harris veer in different directions on pharma

Harris aims to broaden some IRA provisions, including Medicare drug price negotiation, while Trump has adopted a more industry-friendly approach.

By Amy Baxter • Oct. 15, 2024

UnitedHealth, CVS push to remove FTC Chair Lina Khan from PBM case

Attorneys argue Khan and two other commissioners are biased against pharmacy benefit managers and should recuse themselves from an ongoing lawsuit against the middlemen.

By Emily Olsen • Oct. 10, 2024